Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation Part II

Circulation

Volumn 108, Issue 17, 2003, Pages 2041-2048

  Szmitko, Paul E ^b   Wang, Chao Hung ^b   Weisel, Richard D ^b   Jeffries, Greg A ^b   Anderson, Todd J ^a   Verma, Subodh ^b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; LECTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3;

ATHEROSCLEROSIS; CELL ACTIVATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; INFLAMMATION; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

ANIMALS; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASE 9; PHOSPHOLIPASES A; STEM CELLS; VASCULAR DISEASES;

EID: 0242318334     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000089093.75585.98     Document Type: Review

References (96)

1. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105:546-549.
2. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol. 1999;31:23-37.
3. Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical applications. Am J Cardiol. 2002;90(suppl):40L-48L.
4. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
6. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
7. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation. Circulation. 2003;108:1917-1923.
8. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther. 2002;95:89-100.
9. Mehta JL, Li D. Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. J Am Coll Cardiol. 2002;39:1429-1435.
10. Yoshida H, Kondratenko N, Green S, et al. Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J. 1998;334:9-13.
11. Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73-77.
12. Aoyama T, Chen M, Fujiwara H, et al. LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells. FEBS Lett. 2000;467:217-220.
13. Honjo M, Nakamura K, Yamashiro K, et al. Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci U S A. 2003;100:1274-1279.
14. Jono T, Miyazaki A, Nagai R, et al. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett. 2002;511:170-174.
15. Cominacini L, Fratta Pasini A, Garbin U, et al. The platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells. J Am Coll Cardiol. 2003;41:499-507.
16. Chen M, Kakutani M, Minami M, et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2000;20:1107-1115.
17. Li DY, Chen HJ, Staples ED, et al. Oxidized low-density lipoprotein receptor LOX-1 and apoptosis in human atherosclerotic lesions. J Cardiovasc Pharmacol Ther. 2002;7:147-153.
18. Li DY, Zhang YC, Philips MI, et al. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res. 1999;84:1043-1049.
19. Morawietz H, Duerrschmidt N, Niemann B, et al. Induction of the oxLDL receptor LOX-1 by endothelin-1 in human endothelial cells. Biochem Biophys Res Commun. 2001;284:961-965.
20. Mehta JL, Li DY. Identification and autoregulation of receptor for ox-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun. 1998;248:511-514.
21. Li D, Singh RM, Liu L, et al. Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells. Cardiovasc Res. 2003;57:238-243.
22. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol. 2000;20:1116-1122.
23. Chen H, Li D, Saldeen T, Mehta JL. Transforming growth factor-β1 modulates oxidatively modified LDL-induced expression of adhesion molecules: role of LOX-1. Circ Res. 2001;89:1155-1160.
24. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation. 2000;101:2889-2895.
25. Kume N, Murase T, Moriwaki H, et al. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998;83:322-327.
26. Li D, Liu L, Chen H, et al. LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:816-821.
27. Kataoka H, Kume N, Miyamoto S, et al. Oxidized LDL modulates Bax/Bcl-2 through the lectin-like Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:955-960.
28. Cominacini L, Pasini AF, Garbin U, et al. Oxidized low density lipoprotein (oxLDL) binding to oxLDL receptor-1 in endothelial cells induces the activation of NF-κB through an increased production of intracellular reactive oxygen species. J Biol Chem. 2000;275:12633-12638.
29. Li D, Liu L, Chen H, et al. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation. 2003;107:612-617.
30. Kakutani M, Masaki T, Sawamura T. A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. Proc Natl Acad Sci U S A. 2000;97:360-364.
31. Coughlin SR. Thrombin signalling and protease activated receptors. Nature. 2000;407:258-264.
32. Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest. 2003;111:25-27.
33. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD. Protease activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci. 2001;22:146-152.
34. Cheung WM, D'Andrea MR, Andrade-Gordon P, et al. Altered vascular injury responses in mice deficient in protease activated receptor-1. Arterioscler Thromb Vasc Biol. 1999;19:3014-3024.
35. q and Gβγ regulate PAR-1 signaling of thrombin-induced NF-κB activation and ICAM-1 transcription in endothelial cells. Circ Res. 2002;91:398-405.
36. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, et al. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 2000;404:609-613.
37. Vergnolle N, Derian CK, D'Andrea MR, et al. Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. J Immunol. 2002;169:1467-1473.
38. Klarenbach SW, Chipiuk A, Nelson RC, et al. Differential actions of PAR2 and PAR1 in stimulating human endothelial cell exocytosis and permeability: the role of Rho-GTPases. Circ Res. 2003;92:272-278.
39. Chi L, Li Y, Stehno-Bittel L, et al. Interleukin-6 production by endothelial cells via stimulation of protease activated receptors is amplified by endotoxin and tumor necrosis factor-a. J Interferon Cytokine Res. 2001;21:231-240.
40. Hamilton JR, Frauman AG, Cocks TM. Increased expression of protease activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res. 2001;89:92-98.
41. Hamilton JR, Moffatt JD, Frauman AG, et al. Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries. J Cardiovasc Pharmacol. 2001;38:108-119.
42. Robin J, Kharbanda R, Mclean P, et al. Protease-activated receptor 2-mediated vasodilation in humans in vivo: role of nitric oxide and prostanoids. Circulation. 2003;107:954-959.
43. Marutsuka K, Hatakeyama K, Sato Y, et al. Protease activated receptor-2 (PAR2) mediates smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Res. 2002;107:271-276.
44. Bretschneider E, Kaufmann R, Braun M, et al. Evidence for proteinase-activated receptor-2 (PAR-2) mediated mitogenesis in coronary artery smooth muscle cells. Br J Pharmacol. 1999;126:1735-1740.
45. Dabbagh K, Laurent GJ, McAnulty RJ, et al. Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR1 mediated mechanism. Thromb Haemost. 1998;79:405-409.
46. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234.
47. Chung AWY, Jurasz P, Hollenberg MD, et al. Mechanisms of action of proteinase activated receptor agonists on human platelets. Br J Pharmacol. 2002;135:1123-1132.
48. Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003;304:855-861.
49. 2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148-1155.
50. 2, platelet-activating factor acetylhydrolase: a potential new risk for coronary artery disease. Atherosclerosis. 2000;150:413-419.
51. 2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302-1306.
52. 2, platelet activating factor acetylhydrolase. Atheroscler Suppl. 2002;3:57-68.
53. 2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999;19:2909-2917.
54. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479-487.
55. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988;85:2805-2809.
56. Kume N, Cybulsky MI, Gimbrone MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 1992;90:1138-1144.
57. Wu R, Huang YH, Elinder LS, et al. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol. 1998;18:626-630.
58. Stiko A, Regnstrom J, Shah PK, et al. Active oxygen species and lysophosphatidylcholine are involved in oxidized low density lipoprotein activation of smooth muscle cell DNA synthesis. Arterioscler Thromb Vasc Biol. 1996;16:194-200.
59. Hsieh CC, Yen MH, Liu HW, et al. Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. Atherosclerosis. 2000;151:481-491.
60. 2 diminishes the death-inducing effects of oxidized LDL on human monocyte-macrophages. FEBS Lett. 2001;505:357-363.
61. Menschikowski M, Kasper M, Lattke P, et al. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis. 1995;118:173-181.
62. Schiering A, Menschikowski M, Mueller E, et al. Secretory nonpancreatic (group II) phospholipase A2 (sPLA2) releases precursors of important mediators of inflammation from phospholipids. Atherosclerosis. 1999;144:73-78.
63. 2 group IIA on lipoproteins and in atherogenesis. Eur J Clin Invest. 2002;32:383-393.
64. 2 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 2000;20:1276-1282.
65. 2 elicits proinflammatory changes and upregulates the surface expression of fas ligand in monocytic cells potential relevance for atherogenesis. Circ Res. 2002;90:38-45.
66. 2 and TNF-receptor superfamily signaling: implications for the inflammatory response in atherogenesis. Circ Res. 2002;91:681-688.
67. 2. Arterioscler Thromb Vasc Biol. 1999;19:1284-1290.
68. 2 in atherosclerosis, 2: potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol. 1999;19:1291-1298.
69. Kugiyama K, Ota Y, Sugiyama S, et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol. 2000;86:718-722.
70. 2 predict coronary events in patients with coronary artery disease. Circulation. 1999;100:1280-1284.
71. Spina]e FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
72. Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery disease. Clin Cardiol. 2003;26:55-59.
73. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251-262.
74. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
75. Morgan AR, Zhang B, Tapper W, et al. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med. 2003;81:321-326.
76. Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR γ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23:283-288.
77. Noji Y, Kajinami K, Kawashiri MA, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med. 2001;39:380-384.
78. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic varioation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579-1585.
79. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769-775.
80. Lijnen HR, VanHoef B, Lupu F, et al. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol. 1998;18:1035-1045.
81. Amorino GP, Hoover RL. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am J Pathol. 1998;152:199-207.
82. Mason DP, Kenagy RD, Hasenstab D, et al. Matrix metlalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res. 1999;85:1179-1185.
83. Morishige K, Shimokawa H, Matsumoto Y, et al. Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. Cardiovasc Res. 2003;57:572-585.
84. Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J. 2001;141:211-217.
85. Belaaouaj AA, Li A, Wun TC, et al. Matrix metalloproteinases cleave tissue factor pathway inhibitor: effects on coagulation. J Biol Chem. 2000;275:27123-27128.
86. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625-637.
87. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403-409.
88. Szmitko PE, Fedak PWM, Weisel RD, et al. Endothelial progenitor cells: new hope for a broken heart. Circulation. 2003;107:3093-3100.
89. Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation. 2002;105:732-738.
90. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 2000;95:952-958.
91. Hill JM, Zalos G, Halcox JPS, et al. Circulating endothelial progenitor cells, vascular function and cardiovascular risk. N Engl J Med. 2003;348:593-600.
92. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res, 2001;89:e1-e7.
93. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via PI3-kinase/Akt pathway. J Clin Invest. 2001;108:391-397.
94. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108:399-405.
95. Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003;92:1049-1055.
96. Verma S, Kuliszewski MA, Mickle DAG, et al. C-reactive protein attenuates endothelial progenitor cell survival and differentiation. Can J Cardiol. 2002;18(suppl B):325.